Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Adjuvants Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The oncology adjuvants market size has grown...
-
Dublin, April 10, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030" report has been added to ResearchAndMarkets.com's offering.The...
-
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
-
The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technologyThe agreement may be...
-
Oslo, Norway, 16 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management...
-
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. ...
-
Responses observed in three out of six patients Recruitment into the randomized part of the trial underway Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused...
-
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination...
-
Oslo, Norway, 25 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, have today presented at the ChinaBio...
-
Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results...